Adverio Pharma GmbH v. Sandoz Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Adverio Pharma GmbH (Germany); Bayer AG (Germany); Bayer HealthCare Pharmaceuticals Inc. (Delaware)
  • Defendant: Sandoz Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00321, D. Del., 03/23/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because the Defendant, Sandoz Inc., is a corporation organized and existing under the laws of the State of Delaware.
• Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the drug ADEMPAS® constitutes an act of patent infringement.
• Technical Context: The dispute centers on pharmaceutical polymorphism, where the specific crystalline solid-state form of an active pharmaceutical ingredient is claimed to be a distinct, patentable invention.
• Key Procedural History: This is a Hatch-Waxman action initiated in response to Defendant's notification, via a Paragraph IV Certification letter, of its ANDA filing with the U.S. Food and Drug Administration. The patent-in-suit is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") in connection with Plaintiffs' ADEMPAS® product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,503,469 - "Forms of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3-4-B]Pyridino-3-Yl] Pyrimidino-5-Yl} Methyl Carbamate"

• Patent Identification: U.S. Patent No. 12,503,469, "Forms of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3-4-B]Pyridino-3-Yl] Pyrimidino-5-Yl} Methyl Carbamate," issued December 23, 2025 (the "'469 Patent").

The Invention Explained

• Problem Addressed: Prior art methods for preparing the active pharmaceutical ingredient riociguat resulted in a product that required further purification, and the specific solid-state forms of the compound were not well-characterized '469 Patent, col. 2:57-63 '469 Patent, col. 3:1-11 In pharmaceutical development, identifying stable and pure crystalline forms is a critical technical challenge to ensure consistent product quality and performance.
• The Patented Solution: The invention discloses the discovery and characterization of several distinct solid forms (polymorphs and solvates) of riociguat '469 Patent, col. 5:15-25 The patent specifically identifies a thermodynamically stable crystalline form, "Modification I," which is distinguished from other forms by its unique X-ray powder diffraction (XRPD) pattern '469 Patent, abstract '469 Patent, col. 7:39-43
• Technical Importance: Characterizing a stable crystalline polymorph is crucial for drug manufacturing, as it directly impacts the drug's stability, dissolution rate, and bioavailability, thereby ensuring product consistency and therapeutic efficacy.

Key Claims at a Glance

• The complaint asserts independent claim 5 '469 Patent, col. 37:28-43 Compl. ¶28
• The essential elements of independent claim 5 are:
  • A method for treating pulmonary hypertension associated with thromboembolism (CTEPH).
  • The method comprises administering a composition containing a therapeutically effective amount of the compound of formula (I) (riociguat) and a pharmaceutically acceptable carrier.
  • In the composition, more than 90 percent by weight of the compound is in the crystalline form of "Modification I."
  • The compound has an X-Ray powder diffractogram comprising peak maxima at 2 Theta angles of 6.7, 9.1, and 17.8.
• The complaint alleges infringement of "at least claim 5," which may suggest an intent to assert additional claims later in the proceedings Compl. ¶28

III. The Accused Instrumentality

Product Identification

• The accused instrumentalities are Sandoz's proposed generic riociguat tablets in 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg dosage strengths, for which Sandoz submitted ANDA No. 219225 to the FDA Compl. ¶8

Functionality and Market Context

• The Sandoz products are generic versions of Plaintiffs' ADEMPAS® tablets Compl. ¶1 The complaint alleges the products contain the active ingredient riociguat in a specific crystalline form, "Modification I," which is defined by a characteristic X-ray powder diffraction pattern Compl. ¶27 The complaint includes a chemical structure diagram of the riociguat compound, also referred to as the compound of formula (I) Compl. p. 6
• The products are intended for commercial manufacture and sale in the United States upon FDA approval, positioning them as direct competitors to Plaintiffs' branded ADEMPAS® product Compl. ¶1 Compl. ¶9

IV. Analysis of Infringement Allegations

'469 Patent Infringement Allegations

• Identified Points of Contention:
  • Technical Questions: The central dispute will likely be factual and evidentiary. A key question for the court will be whether the riociguat in Sandoz's ANDA product is, in fact, the specific "Modification I" crystalline form as claimed. The complaint's allegations regarding the product's physical form are made "on information and belief," and the case may turn on analytical data (such as XRPD results) produced during discovery Compl. ¶27

V. Key Claim Terms for Construction

• The Term: "crystalline form of Modification I"
• Context and Importance: The determination of infringement hinges entirely on whether Sandoz's product contains this specific polymorph. The definition and scope of this term, which is structurally defined by its XRPD pattern, will be central to the litigation.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party may argue that the term is defined by the express language of claim 5, which requires only the presence of XRPD peaks at 2 Theta angles of 6.7, 9.1, and 17.8 '469 Patent, col. 37:40-43 The patent specification identifies these three peaks as the "preferabl[e]" way to characterize the form, which could support an argument that meeting this preferred definition is sufficient '469 Patent, col. 7:42-43
  • Evidence for a Narrower Interpretation: A party may contend that the term should be construed more narrowly in light of the full specification. The patent discloses a more extensive list of ten characteristic peaks for Modification I, stating the form "can be characterized unambiguously" by that full set '469 Patent, col. 7:39-42 This could be used to argue that a product must substantially conform to the broader pattern, not just the three preferred peaks, to fall within the claim's scope.

VI. Other Allegations

• Indirect Infringement: The complaint alleges active inducement of infringement, stating that Sandoz plans and intends for its ANDA Products to be used in an infringing manner upon approval Compl. ¶32 The basis for this allegation is that Sandoz's proposed product labeling will instruct physicians and patients to administer the drug for the treatment of CTEPH, thereby inducing infringement of the patented method Compl. ¶28 Compl. ¶32
• Willful Infringement: The complaint does not contain allegations of willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two primary questions:

• A core issue will be one of evidentiary proof: What will analytical testing of Sandoz's generic product reveal? Does the crystalline form of riociguat contained within it factually meet the structural limitations of "Modification I," specifically by exhibiting the X-ray powder diffraction peaks required by claim 5 of the '469 Patent?
• A related question may concern claim construction: What is the full and proper scope of the term "crystalline form of Modification I"? The court may need to decide whether infringement requires the presence of only the three XRPD peaks explicitly recited in claim 5, or if the broader characterization provided in the patent's specification imposes additional, narrowing limitations on the claim's scope.